Cargando…

Identification of Targets for Subsequent Treatment of Crohn’s Disease Patients After Failure of Anti-TNF Therapy

BACKGROUND: Anti-TNF medications are the first-line treatment for Crohn’s Disease (CD), despite the fact that a significant portion of the population continues to be ineffectively treated. This research aims to discover accurate intervention targets for the follow-up of anti-TNF non-responders using...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yao, Yao, Yang, Liu, Zhang, Zhe, Wang, Binbin, Feng, Baisui, Liu, Zhanju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590116/ https://www.ncbi.nlm.nih.gov/pubmed/37868830 http://dx.doi.org/10.2147/JIR.S422881

Ejemplares similares

Anti-TNF Therapy in Crohn’s Disease
por: Adegbola, Samuel O., et al.
Publicado: (2018)

Case Report: Anti-TNF Treatment Failure in a Patient With Immune Checkpoint Inhibitor-Induced Severe Colitis
por: Fang, Leilei, et al.
Publicado: (2022)

Critical roles of bile acids in regulating intestinal mucosal immune responses
por: Sun, Ruicong, et al.
Publicado: (2021)

Disseminated Tuberculosis in a Patient Taking Anti-TNF Therapy for Crohn's Disease
por: Wang, Ming-Hsi, et al.
Publicado: (2015)

Case report: Single-cell mapping of peripheral blood mononuclear cells from a patient with both Crohn’s disease and isolated congenital asplenia
por: Pu, Dan, et al.
Publicado: (2022)

Regulatory T cells in Crohn's disease following anti‐TNF‐α therapy
por: Chiba, Toshimi, et al.
Publicado: (2019)

Anti-TNF Therapies Suppress Adipose Tissue Inflammation in Crohn’s Disease
por: Boronat-Toscano, Albert, et al.
Publicado: (2022)

Intestinal Tuberculosis Masquerading as Crohn's Disease? A Case of Disseminated Tuberculosis after Anti-TNF Therapy for Suspected Crohn's Disease
por: Abadir, Alexander P., et al.
Publicado: (2019)

Earlier anti-TNF therapy reduces the risk of malnutrition associated with alterations in body composition in patients with Crohn’s disease
por: Wang, Yuexin, et al.
Publicado: (2023)

Anti-TNF-α Therapy Suppresses Proinflammatory Activities of Mucosal Neutrophils in Inflammatory Bowel Disease
por: Zhang, Cui, et al.
Publicado: (2018)

Effect of Anti-TNF Therapy on Mucosal Apoptosis Genes Expression in Crohn's Disease
por: Lykowska-Szuber, Liliana, et al.
Publicado: (2021)

Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
por: Cassandra, Rayer, et al.
Publicado: (2022)

Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
por: Rayer, Cassandra, et al.
Publicado: (2023)

Efficacy of enteral nutrition in patients with Crohn’s disease on maintenance anti-TNF-alpha antibody therapy: a meta-analysis
por: Hirai, Fumihito, et al.
Publicado: (2019)

Pulmonary Tuberculosis After Therapy with Anti-Tumor Necrosis Factor (TNF) for Crohn Disease: A Case Report
por: da Silva, Douglas Inomata Cardoso, et al.
Publicado: (2021)

Correlation Among Body Composition Parameters and Long-Term Outcomes in Crohn's Disease After Anti-TNF Therapy
por: Ando, Katsuyoshi, et al.
Publicado: (2022)

The influence of anti-TNF therapy on the magnetic resonance enterographic parameters of Crohn’s disease activity
por: Eder, Piotr, et al.
Publicado: (2015)

Paradoxical SAPHO syndrome observed during anti-TNFα therapy for Crohn’s disease
por: Amano, Hitoshi, et al.
Publicado: (2017)

Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease
por: Chaparro, María, et al.
Publicado: (2019)

Anti-TNF Therapy Before Intestinal Surgery for Crohn’s Disease and the Risks of Postoperative Complications
por: Soop, Mattias, et al.
Publicado: (2021)

Prophylactic Antitubercular Therapy Is Associated With Accelerated Disease Progression in Patients With Crohn's Disease Receiving Anti-TNF Therapy: A Retrospective Multicenter Study
por: Liu, Fen, et al.
Publicado: (2022)

Dysregulation of CD177(+) neutrophils on intraepithelial lymphocytes exacerbates gut inflammation via decreasing microbiota-derived DMF
por: Chen, Huimin, et al.
Publicado: (2023)

Alterations and Potential Applications of Gut Microbiota in Biological Therapy for Inflammatory Bowel Diseases
por: Pu, Dan, et al.
Publicado: (2022)

Anti-TNF Exposure during Pregnancy in Crohn's Disease Patients
por: Silva, Elen Farinelli de Campos, et al.
Publicado: (2018)

PREDICTIVE FACTORS FOR LOSS OF RESPONSE TO ANTI-TNF IN CROHN’S DISEASE
por: dos SANTOS, Byanca Rossetti Moreira, et al.
Publicado: (2020)

Intestinal healing after anti-TNF induction therapy predicts long-term response to one-year treatment in patients with ileocolonic Crohn’s disease naive to anti-TNF agents
por: Eder, Piotr, et al.
Publicado: (2015)

Understanding anti‐TNF treatment failure: does serum triiodothyronine‐to‐thyroxine (T3/T4) ratio predict therapeutic outcome to anti‐TNF therapies in biologic‐naïve patients with active luminal Crohn's disease?
por: Lin, Simeng, et al.
Publicado: (2022)

Coexisting Crohn's Disease and Takayasu's Arteritis in Two Patients Treated with Anti-TNF-α Therapies
por: Ratuapli, S., et al.
Publicado: (2010)

Chronic Inflammatory Demyelinating Polyneuropathy Following Anti-TNF-α Therapy With Infliximab for Crohn's Disease
por: Kamel, Amir Y., et al.
Publicado: (2016)

Evaluation of changes in intestinal microbiota in Crohn’s disease patients after anti-TNF alpha treatment
por: Sanchis-Artero, Laura, et al.
Publicado: (2021)

Review of local injection of anti-TNF for perianal fistulising Crohn’s disease
por: Adegbola, Samuel O., et al.
Publicado: (2017)

Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Mucosal IL13RA2 expression predicts nonresponse to anti‐TNF therapy in Crohn's disease
por: Verstockt, Bram, et al.
Publicado: (2019)

Renal Cell Carcinoma in Fistulizing Crohn's Disease Patient Who Received Anti-TNF α Therapy
por: Albishi, Abdullah Mohammed, et al.
Publicado: (2021)

Landscape of sialylation patterns identify biomarkers for diagnosis and prediction of response to anti-TNF therapy in crohn’s disease
por: Ye, Chenglin, et al.
Publicado: (2022)

Anti‐TNFα induced lupus due to infliximab therapy in a patient with concurrent Crohn's disease
por: Sharma, Akanksha, et al.
Publicado: (2023)

Prediction and Verification of Potential Therapeutic Targets for Non-Responders to Infliximab in Ulcerative Colitis
por: Lyu, Xue, et al.
Publicado: (2023)

Anti-TNF-α Monoclonal Antibody Therapy Improves Anemia through Downregulating Hepatocyte Hepcidin Expression in Inflammatory Bowel Disease
por: Shu, Weigang, et al.
Publicado: (2019)

Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti‐TNF therapy in a tuberculosis endemic region
por: Ye, Lingna, et al.
Publicado: (2020)

The Degree of Ulcerative Colitis Burden of Luminal Inflammation score is superior to predicting medium- to long-term prognosis in patients with active ulcerative colitis
por: Chen, Liang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5lmjar84i2ofjj3rbrqfmtig4n